In reply

Oncologist

Volumn 20, Issue 3, 2015, Pages e5-

  Baratti, Dario ^a   Kusamura, Shigeki ^a   Maggi, Claudia ^a   Debraud, Filippo ^a   Deraco, Marcello ^a   Dibartolomeo, Maria ^a   Pietrantonio, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; COLLOID CARCINOMA; CYTOREDUCTIVE SURGERY; HUMAN; LETTER; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; FEMALE; MALE; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI;

EID: 84925394189     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-423     Document Type: Letter

References (8)

1. Overman MJ, Eng C, Matamoros A et al. Challenges of efficacy assessments in pseudomyxoma peritonea. The Oncologist 2015;20:335-336.
2. Pietrantonio F, Maggi C, Fanetti G et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. The Oncologist 2014;19:845-850.
3. Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In: Bosman FT, Carneiro F, Hruban RH et al., eds. WHO Classification of Tumors of the Digestive System. Vol. 3. Lyon, France: International Agency for Research on Cancer, 2010:93-102.
4. Misdraji J, Yantiss RK, Graeme-Cook FM et al. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003;27:1089-1103.
5. Carr NJ, Finch J, Ilesley IC et al. Pathology and prognosis in pseudomyxoma peritonei: A review of 274 cases. J Clin Pathol 2012;65:919-923.
6. Mohamed F, Gething S, Haiba M et al. Clinically aggressive pseudomyxoma peritonei: A variant of a histologically indolent process. J Surg Oncol 2004;86:10-15.
7. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681-685.
8. Farquharson AL, Pranesh N, Witham G et al. A phase II studyevaluatingthe use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008;99:591-596.